Biotech

All Articles

Rivus' phase 2 obesity-related heart failure trial reaches endpoint

.Rivus Pharmaceuticals has actually plumped up the prospects of its fat-busting, muscle-sparing medi...

Ovid halts preclinical work, IV system after soticlestat fail

.Ovid Therapy presently showed last month that it was actually trimming back its head count as the c...

Eli Lilly opens $700M nucleic acid R&ampD facility in Boston ma Seaport

.Eli Lilly has actually opened a $700 million R&ampD facility in the Boston ma Port, increasing its ...

Boundless Bio makes 'moderate' layoffs five months after $100M IPO

.Simply 5 months after securing a $one hundred million IPO, Boundless Bio is currently giving up som...

Halda's $126M will definitely progress 'hold and kill' cyst medicines

.The initial stages of oncology R&ampD aren't short of appealing new techniques, as well as Halda Th...

Lykos 'disappointments' not making known research offenses with publisher

.Psychopharmacology has drawn 3 short articles concerning midstage clinical test data assessing Lyko...

Analysts explore Avidity's DMD gain, disclosing distinctions in records

.Avidity Biosciences satisfied real estate investors with phase 1/2 data in Duchenne muscular dystro...

Actinogen's cortisol blocker falls short phase 2 depression study

.Actinogen Medical's cortisol blocker has actually missed the major endpoint of a phase 2 study in a...

Bivictrix makes a decision going exclusive only method to take ADC into facility

.Antibody-drug conjugates (ADCs) have gone to the facility of several a billion-dollar biobuck licen...

TPG tops up funds to $580M for expenditures across lifestyle scientific researches

.Property supervisor TPG, which has assisted biotechs including Sionna Therapies and Santa Clam Ana ...